Augnito

States plainly that it owns and trains its own AI models rather than orchestrating someone else's, and the evidence supports it: separate speech models tuned per medical specialty is a first party training decision, not something achievable by prompting a general purpose API. The parent's transcription heritage is a services business, but the product assessed here is model work.

Not assessed. Vendor materials describe notes and letters being generated and transferred into the electronic patient record but do not describe the review gate between generation and transfer, and no acceptance rate, edit burden figure or confidence threshold was located. Given the product also captures clinical coding and produces outbound clinical letters, both of which carry consequences beyond the chart, the review step is the first thing to establish in writing.

Useful architectural disclosure undermined by unfalsifiable accuracy language. On the positive side, Augnito describes a genuinely distinctive design: it owns and trains its models, and ships multiple speech models tuned to specific specialties rather than one general model behind specialty templates, which is a structural choice a buyer can interrogate. Against that, the accuracy claims are the weakest in this category. Spectra is marketed at 99.9 percent accurate speech recognition with no methodology, reference standard or denominator, and Omni's materials claim transcription with ABSOLUTE ACCURACY, which is not a property any speech system possesses and cannot be tested. A vendor competing on measurable accuracy should publish measurements.

No peer reviewed study, controlled evaluation or independent assessment located. NHS trust and private provider adoption is asserted across UK and global deployments, and the parent has a long NHS transcription history, but deployment history is not evidence of the AI product's benefit and this index does not treat it as such. Community based nursing deployment is described in case study form rather than measured.

Not assessed. No statement on audio or transcript retention, de identification, or whether customer data is used to train models was located, which matters more here than for most because the vendor explicitly trains its own models and competes on accuracy gained from training data.

Not assessed. Deployment is centred on the NHS and international markets under UK GDPR rather than HIPAA, with operations spanning the United Kingdom and India. A United States buyer should establish business associate agreement posture directly, and should separately ask where processing and any human review occur.

Not assessed. No named or dated attestation and no trust centre located in this pass, though NHS supply would ordinarily require Data Security and Protection Toolkit compliance, which is worth requesting.

Not a regulated medical device and none claimed. Note that Omni is described as delivering NHS approved suggestive feedback, a phrase worth clarifying with the vendor, since clinical suggestion sits closer to regulated territory than transcription does and approval by a health system is not a regulatory classification.

The most specific engagement with accent variation of any vendor in this index, and simultaneously the clearest case of a vendor asserting rather than demonstrating it. Augnito does not gesture at multilingual support; it NAMES the accents it claims to handle, including Indian English, African English, Welsh, Scottish and Irish, alongside capture in more than 37 languages and per specialty speech models. Naming the specific speaker populations rather than hiding behind a language count is meaningfully better than the category norm, and this index's standing concern is precisely that speech models degrade on accents underrepresented in training data. But the marketing frames the product as ACCENT AGNOSTIC and ABSOLUTELY ACCURATE, which converts a measurable property into an unfalsifiable claim. Of every vendor assessed here, this is the one that should publish word error rates broken down by accent, because it is the one selling on them. Doing so would move this to A immediately.

Integration is offered as a capability rather than a fixed list, through an API and SDK designed to add speech and voice command into clinical software, EPR, PACS and RIS systems, alongside direct note and letter transfer into the electronic patient record. Covering radiology reporting systems as well as record systems is broader than most scribes attempt. Held at B because named production integrations were not enumerated or verified in this pass, so breadth is architectural rather than demonstrated.

Not assessed. Cloud delivered across laptops, tablets and smartphones with no voice profile training required, but no hosting region, residency option or sub processor detail was located. Given operations spanning the United Kingdom and India, processing location is a specific question rather than a generic one.

Publishes the pricing mechanism but not the price. Materials describe a simple recurring monthly fee with no capital investment required, which tells a buyer the shape of the commitment and is more than silence, but no rate, tier or per clinician figure was located. Compare the vendors graded A on this axis, which publish the mechanism AND the number.

Among the broadest coverage in this category and enumerated rather than implied. Spectra spans more than 55 medical specialties, Omni captures in clinic, over video call and via telemedicine, and coverage explicitly includes general practice, nursing including community based nurses, psychiatry, surgery and cardiology, with a speech model tuned per specialty rather than one model reused. Capture runs to more than 37 languages with live translation. The community nursing use case, where the clinician is rarely near a desktop, is a setting most competitors in this category do not address at all.